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Abstract 
The use of vaccinations has drastically decreased mortality and morbidity rates related to 
infectious disease and has become an intrinsic part of modern health care. However, the fear of 
risks related to vaccines has been partially responsible for the decisions of many parents to delay 
or avoid vaccinating their children. The human papilloma virus (HPV) vaccine specifically is one 
of the most controversial vaccines in current culture due to reports of new onset or exacerbation 
of autoimmune diseases, infertility, and even death following its administration. This review 
synthesizes information regarding the relevance and safety of the HPV vaccine, as well as its 
efficacy in preventing cervical cancer and precancerous lesions. There appears to be a need for 
thorough education regarding concepts of immunity, infection, and vaccine function for those 
hesitant about receiving vaccines. Particularly regarding the HPV vaccine, practitioners should 
be familiar with common reasons for vaccine refusal and be prepared to respond with accurate 
information. 
 Keywords: HPV vaccine, safety, controversial 
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Introduction 
Vaccines have been an intrinsic part of the public health system since the 1800s, and their 
routine use has saved countless lives, nearly eradicating many deadly endemic diseases 
(Davidson, 2019). However, vaccination rates have seen recent decline and this noncompliance 
has led to multiple outbreaks of vaccine-preventable diseases. The movement against vaccination 
promoted by media prominent influencers and the media has fostered a general mistrust of the 
medical community as a whole (Attwell et al., 2019). Perhaps one of the most controversial 
vaccines currently is Gardasil-9, the HPV vaccine. The aim of this review is to synthesize current 
research regarding whether the risks of the HPV vaccine outweigh its efficacy in the health 
promotion of adolescents and young adults. 
Vaccines 
Introduction to Vaccines 
 Vaccines are prepared biological substances that are introduced into the body in order to 
protect individuals from certain diseases (Davidson, 2019). The goal of vaccine administration is 
to prompt an immune response in the body that creates antibodies for a specific pathogen 
(Feemster, 2018). According to the World Health Organization (WHO), vaccines are second 
only to clean water in the effect they have had on the reduction of illness and death and on the 
growth of the general population. Just by vaccinating against diphtheria, tetanus, whooping 
cough and measles, two to three million deaths are prevented annually, worldwide. Smallpox, the 
disease that killed approximately half a billion people, has been completely eradicated because of 
the use of the smallpox vaccine (Davidson, 2019).  
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Immunity and Infection 
 In order to understand how vaccines work, it is important to have an understanding of the 
immune system and the process of fighting infection. Immunity is the mechanism by which the 
body defends itself against infection by a virus, bacteria or other pathogen. There are two main 
aspects to immunity: innate and adaptive. 
 Innate immunity. Innate immunity is the body’s first line of defense and responds to 
foreign substances immediately, distinguishing invading pathogens through the recognition of 
foreign cellular patterns (Moriber, 2014). The innate immune system is present from birth and 
does not require any external stimulation to aid in its development. Innate immunity is 
nonspecific, meaning the innate immune response is the same no matter what type of pathogen is 
invading the body. This is also true when infection with a pathogen happens multiple times, the 
innate immune response has no memory cells and so the response does not change or grow 
stronger. While innate immunity does respond to foreign pathogens immediately, the maximal 
response is usually reached within minutes to hours of when the pathogen is detected (Davidson, 
2019).  
Adaptive immunity. Adaptive immunity develops over time and is dependent upon 
exposure to a specific pathogen. The first time the body is exposed to a specific pathogen, the 
adaptive response is delayed for a few weeks while antibodies are produced, and the infected 
person will display signs of illness. The second time the body is exposed to a pathogen, the 
adaptive response is immediate, and the pathogen is destroyed fast enough that the person does 
not experience signs of illness (Moriber, 2014). Every pathogen has cell-specific protein 
molecules on its surface known as antigens. When the body is exposed to a new antigen, 
specialized immune cells known as B lymphocytes produce Y-shaped proteins called antibodies. 
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The antibodies seek out and bind to the antigen, deactivating the invading pathogen and stopping 
the effects of the disease (Davidson, 2019). Once the body produces antibodies for an antigen, 
the memory of the antigen is stored by the T lymphocytes, creating immunity to the pathogen. T 
lymphocytes can be further broken up into helper and killer T cells. When a pathogen enters the 
body for a second time, helper T cells notify the killer T cells and the pathogen is eradicated. 
Innate and adaptive immunity cells communicate via cell-to-cell contact, and also by chemical 
mediators. These chemical mediators are called cytokines, chemokines and CSFs. Cytokines are 
the primary means of interaction and allow innate immune cells to communicate important 
information about an invading pathogen to adaptive immune cells. The coordination of innate 
and adaptive immunity is essential in order to produce a successful immune response (Moriber, 
2014).  
Herd immunity. Herd immunity occurs when many people in a specific area have been 
vaccinated against a disease, or have immunity to a disease from exposure, and unvaccinated 
people in the same area are also protected from that disease (Davidson, 2019). Vaccinated 
individuals cannot be infected by diseases they have been vaccinated against, and they cannot 
spread infection to others. Therefore, unvaccinated individuals who are part of a larger, 
vaccinated community are protected from certain diseases as there is no one to spread it to them 
(Feemster, 2018). This concept of herd immunity requires a higher ratio of vaccinated 
individuals to unvaccinated individuals depending on the contagiousness of the disease. For 
example, one person infected with either measles or whooping cough can infect 12-18 other 
unvaccinated individuals. This means that 94% of the population would need to be vaccinated to 
stop either of these diseases from spreading (Davidson, 2019). When immunization rates are low, 
there is a greater risk of infection. If infection occurs, it develops into an outbreak, spreading to 
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all of the susceptible individuals in the community. The fewer people immunized, the more the 
outbreak spreads as there is less protection from herd immunity. An outbreak ends when enough 
people become immune to the disease, either through immunization or exposure (Feemster, 
2018).  
 Infection. During the immune system’s primary response to a new pathogen, the affected 
individual will experience signs of infection. Infectious disease can be marked by five stages: 
incubation, prodrome, acute, convalescence, and resolution. Incubation occurs when the invading 
pathogen begins active replication in the body, but no symptoms of illness have been displayed. 
The prodromal stage involves the appearance of symptoms, which may include fever, fatigue, 
headache, and myalgia. In the acute stage the body begins fighting the pathogen, and the host 
experiences the full impact of the process of infection (Grossman, 2014). The innate immune 
response to an infection involves inflammation, which leads to tissue damage and eventually the 
destruction of the pathogen. When a pathogen first enters the body, chemokines alert leukocytes 
to the pathogen’s presence. The leukocytes begin carrying out a process called margination, 
adhesion and transmigration, which involves accumulating and binding to adhesion molecules 
within the vessel walls. When the leukocytes adhere to these molecules, the endothelial cells 
become separated and the leukocytes are able to migrate from the vessels into the body tissue. 
The chemokines lead the leukocytes to the site of infection, followed by macrophages, 
monocytes and neutrophils. These cells complete a process called phagocytosis, where the 
invading pathogen is engulfed, destroyed and excreted by enzymes. Histamine, cytokines and 
plasma proteins are chemical mediators that produce signs of inflammation in the body such as 
heat, swelling, and redness (Grossman, 2014). 
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How Vaccines Work 
 The purpose of a vaccine is to prompt an immune response by the host against a specific 
pathogen, thereby protecting the host from future infection by that pathogen. When an individual 
comes into contact with a pathogen they have been vaccinated against, adaptive immunity will 
take over and the disease will be wiped out before the individual becomes symptomatic 
(Feemster, 2018). Vaccines must achieve a balance between being weak enough not to cause the 
disease symptoms they are protecting against, and being strong enough to stimulate the 
development of antibodies by B cells and memory by T cells. The immunity an individual 
acquires through vaccination is called artificially acquired immunity. This is slightly different 
than naturally acquired immunity, which would occur by having the disease and recovering, but 
it eliminates the symptoms and risks that come with the disease (Davidson, 2019). In order for a 
vaccine to be effective, antibody production must be stimulated, and antibodies need to be 
attracted to a specific pathogen. Antibodies themselves cannot simply be injected into an 
individual to protect against a disease, as they do not work unless they bind to the antigen of a 
specific pathogen. In order to achieve an adequate balance between disease and immunity, 
vaccines do not contain the same number of antigens that an invading pathogen does. The part of 
the pathogen that causes disease and the part that induces antibody response are separated during 
the development of the vaccine, allowing stimulation of the immune system, without 
endangering the health of the individual being vaccinated (Feemster, 2018). 
History of Vaccines 
 The knowledge that survivors of infection from a certain disease become less prone to 
recurring infection with the same disease goes back to ancient Greece, and inoculation against 
smallpox has been reported in China and India from the 1500s to as early as 200 BC (The 
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College of Physicians of Philadelphia, 2019). Inoculation is the process of infecting an individual 
with a pathogen for the purpose of building immunity, while vaccination involves injecting a 
weakened or attenuated pathogen for the purpose of building immunity against the stronger 
pathogen. The first vaccination was not introduced in the United States until the 18th century. In 
1796 an English doctor named Edward Jenner discovered milkmaids he was treating for cowpox 
were not becoming infected with smallpox, the more prevalent disease at that time. Cowpox is a 
similar viral disease to smallpox, but less common and less severe. Jenner then conducted several 
experiments, including inoculating farmers exposed to cowpox with smallpox. The farmers did 
not develop smallpox, so Jenner then inoculated a young boy with cowpox, followed by 
smallpox a few weeks later. The boy did not develop symptoms of smallpox, and Jenner had 
proven cowpox provides immunity against smallpox. Five years later, over 100,000 people 
across Europe had received the first smallpox vaccine.  
Vaccine acceptance was slower in America, as cows in the United States were not 
affected by cowpox and the virus was more difficult to access. This led to the development of 
fraudulent vaccines on the black market, causing harm to those injected and nearly bringing an 
end to the vaccination movement in America. However, Thomas Jefferson established the 
widespread importation of cowpox fluid from Europe and collaborated with doctors in several 
studies to prove smallpox vaccinations were effective. By the early to mid 20th century vaccines 
were being developed to prevent tuberculosis, yellow fever, typhus, pertussis, influenza, measles, 
mumps and polio (Feemster, 2018). 
Vaccine Development 
 During the 20th century when many of the aforementioned diseases were prevalent, 
vaccines were developed based on how quickly they could reduce the incidence of a disease. 
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Current vaccine development is now largely based on benefit versus risk (Feemster, 2018). The 
other factors considered when developing a vaccine include the type of pathogen, the potential 
adverse effects caused by the vaccination, the number of doses needed, the speed of pathogen 
mutation, and the population needing vaccination. It is also important to consider the ease of 
large-scale production, shelf life, storing and transportation conditions, and route of 
administration. A vaccine can be live attenuated, inactivated/killed, subunit, conjugate, 
polyvalent, or combination (Davidson, 2019).  
Live attenuated vaccines contain live pathogens that have been weakened so they do not 
cause the disease but do cause the production of antibodies. Inactivated vaccines render a virus 
unable to reproduce, but still cause an immune response. Killed vaccines are the equivalent of 
inactivated vaccines for bacterial diseases. The immune response is weaker with 
inactivated/killed vaccines and so requires multiple doses to achieve immunity (Davidson, 2019). 
Subunit vaccines use inactivated proteins from bacteria to induce an immune response. Similarly, 
recombinant vaccines use inactivated viral proteins. In recombinant vaccines, the gene that 
makes the protein is inserted into the DNA of a yeast cell. The yeast reproduces, as does the 
DNA, creating a protein which is purified and made into a vaccine. Human papilloma virus 
vaccines are created using this technique (Feemster, 2018). Polyvalent vaccines protect against 
multiple strains of a disease, HPV vaccines are also polyvalent (Davidson, 2019). Conjugate and 
polysaccharide vaccines are similar to subunit vaccines in that they use a sugar or polysaccharide 
found on the capsule of specific bacteria to illicit an immune response, rather than a form of the 
pathogen itself (Feemster, 2018). 
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Objections to vaccination.  
Trends of the anti-vaccine movement tend to rise or fall in relation to outbreaks of 
vaccine-preventable diseases becoming less or more common. Most of the concerns related to 
vaccines today include skepticism about their efficacy and safety, religious objections and 
concern that mandatory vaccinations violate personal liberty. There has been resistance and 
skepticism related to inoculation and vaccination since their inception. Real vaccine resistance 
began to occur when the Vaccine Act of 1853 came into effect in England and Wales, making 
vaccination mandatory for infants in these countries. The act was not received well and sparked 
the formation of the first anti-vaccination movement, the British Anti-Vaccination League. In 
response to the pressure and large following of the Anti-Vaccination League, British Parliament 
issued the Vaccine Act of 1898. This act authorized conscientious objection to vaccination. At 
the start of the Boer War in 1899, vaccination of soldiers against typhoid was made voluntary for 
similar reasons. Because of this only 5% got the vaccine and 58,000 soldiers developed typhoid. 
Mandatory military vaccination was reinstated in Britain after World War I (Davidson, 2019). In 
1852, certain American states began requiring free public education and compulsory attendance. 
Because of the level of contagious disease children would be required to be exposed to, proof of 
smallpox vaccination was required for school attendance. Today, all public schools and most 
private schools and daycares require proof of certain vaccinations or proof of exemption. 
Opposition to vaccines grew more slowly in America because there were no national laws, but 
eventually the Anti-Vaccination Society of America was established in 1879. This was followed 
by two more leagues in New England and New York. Claims began to spread about vaccines, for 
example, that an increase in leprosy at the time was caused by the smallpox vaccine (Davidson, 
2019).  
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The start of the modern anti-vaccination movement in America began in the 1980s with 
the formation of the National Vaccine Information Center (NVIC). This organization was formed 
after a documentary called DPT: Vaccine Roulette was broadcast by WRC-TV. This 
documentary voiced claims of parents who stated their children had been harmed by receiving 
the diphtheria, pertussis, and tetanus (DPT) vaccine. Their claims mentioned developmental 
regression and mental and physical disabilities following DPT vaccination. The station 
reportedly received over 2,000 calls following the broadcast of parents who believed their 
children’s symptoms were also caused by the DPT vaccine (Davidson, 2019). Vaccine scientists 
reported the rate of injury from the DPT vaccine could only feasibly be one in 100,000. Perhaps 
the most well-known claim promoting vaccine resistance was that of Andrew Wakefield in 1998. 
Wakefield claimed research he and 12 colleagues completed proved the measles, mumps, and 
rubella (MMR) vaccine was connected to the development of autism. Wakefield’s article was 
published by The Lancet, a reputable and peer-reviewed scientific journal. The article spread 
across Europe, to America, Australia, and Japan and parents began refusing the MMR vaccine 
for their children. Wakefield’s research was later determined to be fraudulent and inaccurate. 
Ten of his colleagues rejected the article, it was redacted, and Wakefield had his medical license 
revoked. However, the study and rejection of Wakefield’s research could not take back the fact 
that his theory was circulated worldwide (Davidson, 2019). 
Human Papilloma Virus (HPV) 
HPV – The Infection  
 Human papilloma virus is the most common sexually transmitted disease in America, 
affecting over 79 million individuals in their teens and early 20s. Symptoms of this disease are 
not always present, and 90% of the time HPV infections go away on their own and become 
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undetectable after two years. However, when HPV stays in the body it can lead to genital warts 
and certain cancers. The virus does not spread through blood or body fluids, but through skin-to-
skin sexual contact. Human papilloma virus is spread by vaginal, anal, and oral sex and affects 
the vulva, vagina, cervix, penis, scrotum, mouth, and throat. A person may also be infected with 
multiple strains of HPV at once, and it has been determined that most sexually active individuals 
contract HPV at some point in their lives (NYULH, 2019). Since it is spread from skin-to-skin 
contact, the HPV virus affects the mucosal and cutaneous epithelium and causes benign or 
cancerous lesions. It is an oncogenic virus that has developed mechanisms allowing it to escape 
from the host immune defenses, and therefore prolong the length of infection. An individual 
infected with HPV could be infected for several months before the immune system initiates a 
response. Because of this characteristic of the disease, immunosuppressed individuals are at 
increased risk of developing lesions and cancer. However, this delay of the immune response is 
observed in individuals who are immunocompromised as well as those who are not (Ashrafi & 
Salman, 2016).  
 One of the ways HPV avoids detection by the host immune system is its nonlytic 
property. When HPV infects a cell, it does not break it down. This causes less exposure of the 
viral antigen to the T cells, and results in a lack of inflammation. Certain strains of the virus 
contain HPV oncoproteins E5, E6, and E7. These oncoproteins assist in the disruption of the 
functions of major histocompatibility complex class I (MHC I) and the interferon (IFN) pathway. 
E6 and E7 disrupt the IFN pathway by inhibiting IFN production in natural killer (NK) cells. 
This inhibits the NK cells from doing their job in destroying the virus, as the role of IFN is to 
“flag” certain cells for destruction. E5 is located in the endoplasmic reticulum and Golgi body of 
HPV infected cells. E5 retains surface MHC I within the Golgi body, disabling it. This allows the 
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infected cells to evade destruction via cytotoxic T cells and establishes the prolonged length of 
the HPV infection. The persistence of HPV is what leads to the development of malignant 
lesions and cancer (Ashrafi & Salman, 2016).  
HPV and cancer 
There are over 150 types of HPV that infect humans. Forty of those types are linked to 
cancer and nine of those types are known to cause the majority of HPV-related cancers and 
genital warts (NYULH, 2019). These are HPV types six, 11, 16, 18, 31, 33, 45, 52 and 58 (MSD, 
2019). HPV types six and 11 are identified as low risk and cause 90% of genital warts and mild 
cervical dysplasia (NYULH, 2019). About 70% of cervical cancers and 50% of high-grade 
cervical lesions are associated with HPV types 16 and 18 (Niccolai et al., 2017). Along with 
types 16 and 18, types 31, 33, 45, 52 and 58 are also identified as high risk and are responsible 
for most HPV-related cancers (MSD, 2019). 
Cervical cancer. Cervical cancer is the third most common cancer among women across 
the world. Approximately 13,000 new cases and 4,100 deaths from cervical cancer occur each 
year in the US. Cervical cancer occurs at a much higher rate in less developed countries, with 
569,000 cases and 300,000 deaths yearly worldwide. The risk of cervical cancer doubles with the 
first sexual intercourse occurring before age 18 compared with after age 21. Giving birth before 
age 18, and multiple vaginal births (>4) are also risk factors. Smoking can negatively affect 
cervical cells, as well as compromise the immune system. This increases the risk of an HPV 
infection developing into cancer. Human immunodeficiency virus (HIV) infection and prolonged 
use of oral contraceptives (>5 years) also increase the risk of cervical cancer (Johnson, James, 
Marzan & Armaos, 2019).  
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The early clinical presentation of cervical cancer is usually asymptomatic, but commonly 
includes irregular vaginal bleeding and discharge. Later signs include radiating pelvic and lower 
back pain, and bowel or bladder changes such as hematuria. If cervical cancer is suspected, a 
pelvic examination is performed, and any abnormal lesions are biopsied. The definitive 
diagnostic test for cervical cancer is a colonoscopy, followed by histological examination of 
cervical biopsy. The two most common types of cervical cancer are squamous cell carcinoma 
(85%) and adenocarcinoma (25%). Prognosis is generally worse in non-squamous cell 
presentation, as well as in metastasis to the pelvic or para-aortic nodes. Treatment of cervical 
cancer includes surgery, radiation, chemotherapy and immunotherapy. Many of these treatments 
can lead to problems of their own, such as bladder dysfunction, bowel dysfunction, premature 
ovarian failure, sexual dysfunction, lymphedema, fatigue and psychosocial issues (Johnson et al., 
2019).  
Oropharyngeal cancer. While cervical cancer occurs more frequently in less developed 
countries, oropharyngeal cancer is more common in developed countries. Ninety percent of 
oropharyngeal cancers are squamous cell carcinomas. In the United States oropharyngeal cancers 
have increased by 3.9% in men and 2.1% in women. The risk for oropharyngeal cancer increases 
with tobacco and alcohol use, however with HPV positive oropharyngeal cancers, the 
demographic tends to have less tobacco and alcohol exposure. Patients with HPV also tend to be 
in their mid 50s and have a higher socioeconomic class and education. Oropharyngeal cancer 
caused by HPV is also more common in Caucasians and is three times more likely to occur in 
men. Ninety to ninety-five percent of oropharyngeal cancer is caused by HPV type 16, the 
survival of which may be facilitated in the tissue of the tonsils, which are histologically similar 
to cervical tissue. This type of cancer usually presents with a tumor and lymph node involvement 
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in the early stages; however, metastasis is usually delayed (Elrefaey, Massaro, Chiocca, Chiesa 
& Ansarin, 2014). Oropharyngeal cancer caused by HPV usually has a better outcome than other 
oropharyngeal cancers, with a 28% lower risk of death and a 49% lower risk of recurrence. This 
improved prognosis can be due to contracting HPV at a young age, fewer genetic alterations in 
the tumors, higher radiosensitivity, and absence of field cancerization. Because of better 
prognosis, nonsurgical treatments such as chemotherapy and radiation are preferred for this type 
of cancer. Side effects of this treatment are xerostomia, chronic aspiration, dysphagia, and 
chronic fatigue. In order to decrease these side effects, minimally invasive procedures such as 
transoral robotic surgery (TORS), which uses lower adjunct doses of chemotherapy and radiation 
(Elrefaey et al., 2014).  
HPV vaccine 
 Gardasil was the first HPV vaccine developed and was approved by the FDA in 2006. 
Gardasil is also known as the quadrivalent vaccine, and protects against HPV types six, 11, 16 
and 18 (Johnson et al., 2019). In 2009 a bivalent vaccine known as Cervarix was approved to 
cover just HPV types 16 and 18 (Elrefaey et al., 2014). The only HPV vaccine currently 
available in the United States is the 9-valent vaccine or Gardasil-9, approved in 2014. Gardasil-9 
covers HPV types six, 11, 16, 18, 31, 33, 45, 52 and 58, the nine types known to cause the 
majority of HPV-related cancers (Johnson et al., 2019). The HPV vaccine is recommended for 
11 to 12-year-old girls and boys, but it can be started as early as age nine, especially if the patient 
has a history of sexual abuse. It is ideal to receive the vaccine before sexual contact and 
consequential exposure to HPV. However, the HPV vaccine can still be beneficial to individuals 
who are sexually active. While the vaccine cannot treat an existing HPV infection, it can protect 
an individual from certain HPV types they may not yet have been exposed to. The CDC 
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recommends two doses at least six months apart for nine to 14-year-olds, and three doses over 6 
months for those beginning the vaccine series at ages 15 through 26. Response to the vaccine is 
better at younger ages which is why three doses are recommended after the age of 14. The HPV 
vaccine has also recently been approved for men and women ages 27 to 45, as it has been proven 
to still be effective later in life (Mayo Clinic, 2019). Gardasil-9 is composed of virus like 
proteins (VLPs) that closely resemble HPV and stimulate antibodies that also react against the 
HPV virus. The vaccine does not contain live or killed HPV virus or DNA from the virus and is 
therefore not infectious. The VLPs have been proven to be highly effective, as they stimulate a 
strong immune response (NIH, 2019). The vaccine contains aluminum as an adjuvant to assist in 
stimulating the immune system, and polysorbate 80 to stabilize the vaccine. The vaccine also 
contains sodium chloride, water, L-histidine (an amino-acid, which makes up a protein), and 
sodium borate (Nicol et al., 2015).   
Controversy 
There are many topics of controversy surrounding the HPV vaccine. The main points of 
dispute include the vaccine’s relevance, efficacy, and safety.  
Relevance 
The relevance of the HPV vaccine is often disputed by those who believe it promotes 
promiscuity in young adults. Some also state that because the vaccine does not cover all strains 
of the virus, there is no point in getting it. Others mention that because of screenings such as pap 
smears and HPV testing, a vaccine is not needed (Holland et al., 2018). 
Promoting promiscuity. One of the most common presumptions about the HPV vaccine 
is that it promotes the promiscuity of young adults by protecting them from the most common 
sexually transmitted disease. There have been multiple peer-reviewed studies completed that 
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disprove this theory. A study done in Canada compared a cohort of eighth-grade girls two years 
before and two years after implementation of the country’s HPV vaccination program. The 
cohort consisted of 260,493 girls, 128,712 of which were eligible for the vaccination program. 
The study measured incidence of pregnancy and sexually transmitted diseases that were non-
HPV related. The study identified 15,441 incidences of pregnancy and sexually transmitted 
diseases out of the entire cohort but found that there was no increased risk in those who received 
the vaccine (Smith, Kaufman, Strumpf & Lévesque, 2015). A recent study in the United States 
compared youth high risk behavior in states that had passed legislation promoting the HPV 
vaccine with states that had not. The study utilized the results of 886,981 Youth Risk Behavior 
Surveillance System (YRBSS) surveys of high school students from 2001-2015. The results of 
this study found no significant difference in sexual behaviors in states that had passed legislation 
compared with those that had not. In states with HPV vaccination legislation there was actually a 
reported decrease in adolescent sexual intercourse by 0.9% and increase in condom use by 
0.96%. Therefore, implementation of the HPV vaccine does not appear to increase the risk of 
sexual behavior in adolescents (Cook, Venkataramani, Kim, Tamimi, & Holmes 2018).  
Real risk of cancer. Because there are many strains of HPV that appear and resolve on 
their own, some may not feel the need to vaccinate against it. While it is true the vaccine does 
not cover all strains of HPV, it does cover the most common strains to cause cancer (ACS, 
2017). Globally each year, HPV causes 570,000 and 60,000 cancer cases in women and men, 
respectively (de Martel, Plummer, Vignat, & Franceschi, 2017). In the United States, HPV 
causes >90% of all cervical and anal cancers, 70% of vaginal, vulvar and oropharyngeal cancers, 
and >60% of penile cancers (CDC, 2019a). Some who oppose the vaccine argue it is not worth 
giving, as cervical cancer only accounts for 0.8% of cancers in the United States (Holland, 
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Rosenberg, Iorio, & Montagnier, 2018). While this is true, cervical cancer kills >4,000 women 
(ASCO, 2019), and oropharyngeal cancer kills >9,000 people (OCF, 2019) every year in the 
United States. There is a way to greatly reduce these numbers, as research has shown 70-90% of 
all HPV-related cancers can be prevented by HPV vaccination (de Martel et al., 2017). Based on 
this evidence, it would seem that vaccination is both justifiable and necessary.  
 Alternative prevention methods. Some sources question the relevance of the HPV 
vaccine in terms of cancer prevention when more desirable alternatives exist such as pap smears 
and HPV tests (Holland et al., 2018). Pap smears and HPV tests are methods of screening that 
may prevent the development of cancer if abnormal cells are caught early enough. Conversely, 
the HPV vaccine prevents most cancer-causing HPV types from ever infecting an individual, 
stopping cancer before it starts. Because the vaccine does not cover every strain of HPV, it is 
important to utilize screening methods in combination with the vaccine. However, pap smears 
cannot be relied on as the primary method of prevention, as they can only diagnose the need for 
further testing by identifying abnormal cervical cells. The majority of HPV-related cancers are 
not cervical cancers, and the pap test cannot prevent these (Simpson, 2018). Human papilloma 
virus tests are done when a pap smear result is abnormal in order to detect the presence of the 
HPV virus, however it does not test for all HPV types. The test does not diagnose cancer but 
determines the presence of an HPV type that may cause cancer. It is usually followed up with 
further testing (Mayo Clinic, 2018). There are currently no FDA approved screening methods for 
men, or for other types of HPV-caused cancers besides cervical cancer (ACS, 2017). This 
includes oropharyngeal cancer, which is the most common type of HPV-caused cancer in the 
United States (Van Dyne et al., 2018). Therefore, the HPV vaccine remains the best overall 
prevention method for HPV and HPV-caused cancers.   
THE HPV VACCINE CONTROVERSY 
 
20 
Efficacy 
 The ability of the HPV vaccine to prevent infection with the virus, the formation of 
cancerous lesions, and the development of cancer is often disputed. 
 Prevention of HPV infection. The initial goal of the HPV vaccine is to prevent the 
development of HPV infection. There have been multiple studies done to prove the efficacy of 
the HPV vaccine. One study determined the vaccine has reduced the prevalence of HPV by 86% 
in the United States over the course of 10 years. This reduction was observed across racial and 
ethnic groups (McClung et al., 2019). A study done in Norway compared a vaccinated cohort to 
a nonvaccinated cohort. Five years post-vaccination, an 81% reduction of HPV infections was 
found in the vaccinated group compared to the unvaccinated group (Feiring et al., 2018). 
Another study done in England from 2010-2016 showed vaccine effectiveness of 82% (Mesher 
et al., 2018). There was a long-term follow-up study done over 12 years in Finland. This study 
analyzed 2,500 serum samples from recipients of Gardasil and Cervarix and found anti-HPV-16 
and anti-HPV-18 antibodies remained stable and higher than they would be from a natural 
infection for up to 12 years following vaccination. These results confirm previous reports of 
long-term protection against HPV (Artemchuk et al., 2019).  
 Prevention of precancerous lesions. It is also important to monitor the development of 
HPV-caused cervical lesions, as these can lead to the development of cervical cancer (Niccolai et 
al., 2017). The vaccine has also shown efficacy in preventing precancerous lesions. A study 
using data from the CDC of over 10,000 women displays how the vaccine is effectively reducing 
the incidence of precancerous lesions. The results of the study indicated that incidence of lesions 
declined in HPV vaccinated women from 55.2% to 33.3% over 6 years. There were also declines 
seen in unvaccinated women (from 51% to 47.3%) suggesting herd immunity (Simon, 2019). A 
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study done in Connecticut showed declines of high-grade cervical lesions from the years 2008-
2015. The rates declined by up to 74%, with greater declines observed in younger women 
(Niccolai et al., 2017). Another study was done in Northern California to demonstrate the 
effectiveness of the vaccine in preventing precancerous lesions in those who began HPV 
vaccination later (>17 years old). Protection against precancerous lesions was observed in 
women with the first dose of three between the ages of 14-20 compared with women who had no 
previous vaccination, or those who began their HPV vaccinations over 21 years old. According 
to this study, those who received >1 HPV vaccine dose were at a significantly decreased risk of 
developing precancerous lesions than those who were unvaccinated (Silverberg et al., 2018). 
Finally, a study from Australia found the rate of cervical lesions decreased by nearly 75% in 
women < 20 years old and by 50% in woman aged 20-24 since the implementation of their 
National HPV Vaccine Program in 2007 (VCCS, 2017).  
 Prevention of cervical cancer. Some sources advocating against the HPV vaccine state 
the vaccine has never been proven to prevent cancer (Holland et al., 2018). However, according 
to evidence-based research, this is simply not true. The primary goal of the HPV vaccine is to 
prevent the development of HPV-related cancers, the most recognized type being cervical 
cancer. One study utilized a mathematical model to determine the natural occurrence of cervical 
cancer and length of protection from HPV the vaccine provides. The model projected that over 
half of cervical cancer-causing HPV infections occur by the age of 20. This means if the vaccine 
protects for 20 years, vaccinating by age 12 would reduce the lifetime risk of developing HPV-
caused cancer by over half (Burger, Kim, Sy & Castle, 2017). Another study aimed to determine 
how protected individuals would be after only receiving part of the recommended three-dose 
vaccine. The study found significant reductions of cervical intraepithelial neoplasia (CIN) in 
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partially vaccinated individuals ages 15-19. CIN1 (mild cervical dysplasia) had an annual 
percentage change (APC) of -9.0%, CIN2 (moderate dysplasia) had an APC of -10.5%, and for 
CIN3 (severe dysplasia) the APC was -41.3%. This study demonstrates even those who are only 
partially vaccinated against HPV will experience decreased incidence of CIN (Benard et al., 
2017). A systematic review compiling data from Medline and Embase determined that CIN2 
incidence decreased by over half in girls aged 15-19 years and by 31% in women aged 20-24 
years up to nine years post-vaccination (Drolet et al., 2019).  
 Prevention of other cancer types. There are about 44,000 new cases of HPV-associated 
cancers per year in the United States, including cervical, vaginal, oropharyngeal, anal, penile and 
vulvar. Oropharyngeal squamous cell carcinoma (SCC) is now the number one cancer caused by 
HPV in the United States, outnumbering cervical cancer cases 18,915 to 11,788 in 2015. The rate 
of oropharyngeal SCC is 2.7% in men and 0.8% in women (Van Dyne et al., 2018). One study 
found a reduction of 88% in oral HPV infections among vaccinated individuals compared with 
unvaccinated individuals. The study also found no evident HPV infection in vaccinated males, 
which seems to indicate a 100% reduction rate. As oropharyngeal SCC is three to five times 
more prevalent in men, this information is vital to increase vaccine coverage in men (Chaturvedi 
et al., 2018). A study done in Norway analyzed the increasing trends in all types of HPV-caused 
cancers that are not monitored by screening methods over the course of 60 years. The study 
determined that the 9-valent HPV vaccine may prevent 478 cancers per year in Norway alone 
(Hansen, Campbell & Nygård, 2018). 
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Safety 
 Perhaps the most disputed topic of controversy regarding the HPV vaccine is its safety. 
There is concern around the safety of the vaccine ingredients, the reported side effects, and the 
reports of infertility, autoimmune disease, and death following HPV vaccination.  
 Ingredients. Two of the most controversial ingredients in the HPV vaccine include 
aluminum and polysorbate 80. Aluminum is the world’s most common metal. It can be found in 
the air, water, dirt, plants, and in food such as flour, dairy products, fruit, and vegetables. The 
average person consumes 7-9 milligrams (mg) of aluminum per day. Aluminum is used in 
vaccines as an adjuvant, meaning it enhances the body’s immune response. Aluminum is used as 
an adjuvant in nearly all infant vaccinations and the amount of aluminum they receive in the first 
six months of life (4.4 mg) is less than the amount found in breast milk (7 mg) or formula (38 
mg) (CHOP, 2018). The amount of aluminum in the HPV vaccine is minute for an adult, 225 
micrograms (mcg) or 0.225 mg (Nicol et al., 2015). There have been studies that attest the 
aluminum in vaccines is harmful, and that it can build up in the body causing neurotoxicity and 
contribute to diseases such as Alzheimer’s (Holland et al., 2018). However, the amount of 
aluminum in the vaccine is so small, one would absorb much more by drinking a glass of tap 
water. Furthermore, according to the Children’s Hospital of Philadelphia (CHOP), all studies 
have not seen consistently high levels of aluminum in Alzheimer’s patients, and causation cannot 
be proven (CHOP, 2018). 
The HPV vaccine also contains 50 mcg of polysorbate 80 (Nicol et al., 2015), used in 
many other vaccines, as well as for an emulsifier in ice cream, cosmetics and medications. In the 
HPV vaccine, polysorbate 80 is used as a stabilizer and emulsifier, to keep the other vaccine 
ingredients evenly distributed (Schwartzberg & Navari, 2018). Some sources say polysorbate 80 
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content in vaccines opens the blood brain barrier (BBB), allowing adjuvants such as aluminum to 
permeate into the brain (Holland et al., 2018). A study done in 1985 is the main source of the 
dangerous claims about polysorbate 80 breaking down the BBB. In this study, large amounts of 
polysorbate 80 were injected into rats and mice and depression of the central nervous system 
resulting in paralysis and ataxia was observed. Based on this study, a safe dosage of polysorbate 
80 was determined to be 1 milliliter (ml) per kilogram (kg) (Varma et al., 1985). One ml equates 
to 1 gram (g), so for an average 45kg adolescent receiving this vaccine, a safe dosage would be 
45g or 45,000,000mcg. This “safe dosage” is 900,000 times larger than the 50mcg found in the 
HPV vaccine. Therefore, in order to have effects like those of the mice in this study, 45g would 
need to be injected intravenously.   
 Side effects. According to the CDC, the most common side effects following HPV 
vaccination are redness and swelling around the injection site, headache, fever, nausea, and 
fatigue (CDC, 2019b). However, the safety of the HPV vaccine has been questioned frequently 
due to reports of more serious adverse effects, and compliance with HPV vaccinations has been 
lower than recommended because of this. The CDC reported that in 2018, 53.7% of girls and 
48.7% of boys were up to date with the HPV vaccine, which was a slight improvement from the 
year before (Jenco, 2019). There have been multiple large-scale studies done to establish the 
overall safety of the HPV vaccine. One study including almost one million girls from two 
different countries compared vaccinated and unvaccinated cohorts. Of the 696,420 girls that were 
vaccinated, exposure to the vaccine was not related to serious adverse effects (Arnheim-
Dahlström, 2013). A long-term follow-up study taking place over the course of eight years 
compared the HPV vaccine with a saline control group. The saline group received the 
vaccination at the 30-month mark, and the groups showed no difference in adverse effects, and 
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no new adverse effects for 8 years following vaccination (Ferris et al., 2014). A more recent 
study also confirmed these findings. The study involved two years of surveillance of 838,991 
recipients of the HPV vaccine for adverse effects; nothing of concern was identified (Donahue et 
al., 2019).  
 Side effects that patients believe to be associated with vaccines can be reported to the 
Vaccine Adverse Event Reporting System (VAERS). One study searched the VAERS database 
for reports of adverse events following HPV vaccination. 97.4% of the 7,244 reports gathered 
from 2014-2017 were determined to be nonserious, including dizziness, injection site reactions, 
syncope, and headache (Shimabukuro et al., 2019). These findings are consistent with the CDC’s 
most commonly listed side effects (CDC, 2019b). The study found that there were 259 reports to 
VAERS out of every one million HPV vaccines given. 2.6% of total reports to VAERS reported 
serious adverse events including anaphylaxis, primary ovarian insufficiency (POI), autoimmune 
disease onset, and death. However, many of these reports did not meet the diagnostic criteria for 
the reported disease, and the two confirmed deaths had no information to suggest that they were 
caused by the HPV vaccine (Shimabukuro et al., 2019). Despite this evidence, the safety of the 
HPV vaccine is still questioned. 
 Primary ovarian insufficiency (POI). There have been some connections between the 
HPV vaccine and POI. Primary ovarian insufficiency occurs in women less than 40 years old and 
causes fluctuation of ovary function leading to ovarian failure. 74%-90% of the time, the cause 
of POI is unknown, and the incidence of POI in early to mid-adolescence is so rare that there are 
no age-specific background rates (Little & Ward, 2014). A case report study was done in 2014, 
focusing on three cases. Case one was a 16-year-old who received the HPV vaccine at age 14. 
Her cycles became irregular and scant in the following year and she was diagnosed with ovarian 
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failure at 16. Case two was an 18-year-old who began taking oral contraceptive pills (OCP) at 12 
years old and received the first HPV vaccine a few months later. The OCP was stopped at age 18 
and the patient experienced amenorrhea for several months before she was diagnosed with 
ovarian failure. Case three was a 17-year-old who received the HPV vaccine at age 14, and 
experienced amenorrhea after the third vaccination dose and experienced symptoms of premature 
menopause a few months later. She was diagnosed with ovarian failure at age 17. However, 
because there is no evidence to suggest that the vaccine initiated POI onset, these case reports 
cannot establish causation. This was stated by the authors of the case reports (Little & Ward, 
2014). A recent cohort study of nearly 200,000 young women was done to evaluate POI in 
relation to the HPV vaccine. From a group of 58,871 women who received the vaccination 
during the study, only one idiopathic case of POI in an adolescent with onset following HPV 
vaccination was identified. Others who developed POI in this study were over the age of 26, 
which is consistent with other population-based studies. If POI were to be triggered by HPV 
vaccination, it would be expected that a higher incidence of POI would occur in younger women 
who were receiving the vaccine. The study found no evidence of increased diagnosis of POI 
following HPV vaccination (Naleway et al., 2018). 
Guillain-Barré syndrome (GBS). Guillain-Barré syndrome is a rare and serious 
autoimmune disease that causes demyelination of the peripheral nervous system, resulting in 
muscle weakness. The onset of GBS is generally not understood, however it is thought to be 
related to molecular mimicry, generally preceded by some type of infection. Onset of GBS has 
been connected to vaccines previously, as there was an increase in the number of cases after the 
swine influenza vaccination in 1976. However, following this incident, GBS has not been 
connected with the influenza vaccine or other vaccines. There have been several large population 
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studies done relating the risk of GBS following HPV vaccination in the United States, England, 
France and Scandinavia. All of these studies found no increase in the incidence of GBS 
following HPV vaccination, except France (Gee, Sukumaran & Weintraub, 2017). In 2017 a 
retrospective cohort study was done following 2.2 million girls, 37% of which received the 
vaccine. The incidence of GBS increased from 0.4 cases per 100,000 in the unvaccinated to 1.4 
cases per 100,000 in the vaccinated (Miranda et al., 2017). However, a separate study was done 
in England in response to the French study. The UK study gave 10.4 million doses of the HPV 
vaccine and observed no increased risk of GBS throughout the next year following vaccination 
(Andrews, Stowe & Miller, 2017). A separate study by the US identified seven cases of GBS 
following administration of >2 million doses of the vaccine. Of those seven cases, only one was 
determined to be a new diagnosis of GBS. Both the UK and the US study support the risk of less 
than one case of GBS per one million doses of HPV vaccine (Gee et al., 2017). This is lower 
than the average rate, as GBS is typically contracted in one to two people out of every 100,000 
(NORD, 2017). 
Complex regional pain syndrome (CRPS) and Postural orthostatic tachycardia 
syndrome (POTS). Complex regional pain syndrome and POTS are both disorders that were not 
originally associated with autoimmunity, but some sources list them as potential autoimmune 
syndromes associated with the HPV vaccine. Complex regional pain syndrome is a chronic pain 
syndrome affecting one limb, and POTS is a form of orthostatic intolerance where the heart rate 
increases abnormally following sitting or standing, and is accompanied by fainting, headaches, 
nausea, dizziness and fatigue. Case reports of CRPS following HPV vaccination in Japan 
resulted in the withdrawal of government recommendation for the vaccine. However, these cases 
were later determined to be unrelated to vaccination by the Global Advisory Committee on 
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Vaccine Safety (GAVCS) (Philips, Patel, Pillsbury, Brotherton & Macartney, 2018). Denmark 
reported two case series of POTS following HPV vaccination, however these reports were 
criticized as they lacked specificity of symptoms. In 2015 the European Medicines Agency 
(EMA) completed a review including data from clinical trials as well as post-marketing literature 
and surveillance to assess the evidence of a causal link between the HPV vaccine and onset of 
POTS or CRPS. The review The EMA review found no increased occurrence of POTS or CRPS 
in HPV vaccinated groups, as the rate of POTS and CRPS in unvaccinated and vaccinated groups 
did not differ. Therefore, there was no causal link between HPV vaccination and disease onset 
(Philips et al., 2018). A study of POTS was done in Finland over the course of 10 years before 
the HPV vaccine was implemented in the country. In 2002 at the start of the study, there were 
two annual cases of POTS out of every 100,000 people. In 2012 at the end of the study, that 
number had increased to 13 annual cases out of every 100,000 people. This increase was 
attributed in part to increased awareness of the condition by physicians (Barboi et al., 2019). This 
study was followed by another Finnish study to assess the incidence of POTS following 
vaccination from 2013-2016. The year the vaccine was introduced, the incidence of CRPS stayed 
the same, and the incidence of POTS actually decreased (Skufca et al., 2018). According to the 
findings from these studies, there is no causal link between the HPV vaccine and the onset of 
POTS or CRPS. 
Autoimmune vasculitis and death. In 2012, six years after the approval of the HPV 
vaccine, a study was published linking the vaccine to fatal autoimmune vasculopathies. The 
study was based on the cases of two young women who died after receiving the HPV vaccine. 
Case one was a 19-year-old who died in her sleep six months after receiving the third dose of 
Gardasil. Case two was a 14-year-old who developed confusion, speech problems, migraines and 
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inability to walk two weeks after receiving her first dose of the vaccine. These symptoms 
resolved, but she was found unconscious 15 days after her second dose and later pronounced 
dead at the hospital. Autopsies were completed for both patients and showed no abnormalities in 
either of their brains that could account for a potential cause of death. The autopsy for case 2 
demonstrated cardiac arrest which lead to ischemic encephalopathy. The study involved 
analyzing samples of brain tissue from the two cases utilizing standard hematoxylin and eosin 
(H&E) staining and immunohistochemical (IHC) methods, which involves incubation, 
counterstaining and observation using a light microscope. The findings showed evidence of 
cross-reactive HPV-16L1 antibodies within the cerebral vasculature, which is believed to have 
caused autoimmune vasculitis in both cases (Tomljenovic & Shaw, 2012).  
 The Centers for Disease Control and Prevention (CDC) issued a response that same year 
to the Tomljenovic article, utilizing a working group made up of professionals with expertise on 
the subject to address the study. These professionals convened from universities including 
Vanderbilt, John’s Hopkins, Columbia and Duke, as well as the FDA. This working group 
identified several scientific concerns with the Tomljenovic article. In order for vasculitis to be 
histologically diagnosed correctly, there would have to be evidence of an infiltrate associated 
with inflammation and destructive changes within the cerebral vessels. This evidence would 
have been clearly observable with normal H&E staining. Of the IHC and H&E images in the 
Tomljenovic article, none of them displays damage to the vessels, or an inflammatory infiltrate. 
The only thing displayed in the images is hemorrhage, which is a common occurrence in autopsy 
specimens (CDC, 2012). Furthermore, an immune-based vasculitis would have been visible as 
obvious inflammation on H&E slides to the pathologist completing the autopsy. However, both 
autopsies of the cases in question determined that there were no brain abnormalities that could 
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have been the cause of death. In fact, the cause of death in case two was determined to be cardiac 
arrest which lead to ischemic encephalopathy. Ischemic encephalopathy is swelling in the brain 
due to a lack of oxygen, caused by the failure of the heart to pump blood (Gorski, 2012). The 
study also lacks the use of negative antibody and tissue control samples. Without these control 
samples, it is not possible to measure immunoreactivity quantitatively, which is something the 
study lists as a limitation (Tomljenovic & Shaw, 2012). The study reports finding HPV-161 
particles in the cerebral vasculature, as well as the walls of some blood vessels. However, the 
CDC working group clarified that antibodies such as HPV cannot be seen with the use of a 
standard light microscope, such as the one reportedly used in the Tomljenovic article. In order to 
view these viral particles, the use of an electron microscope would have been necessary, and its 
use is not reported in the article. Finally, there was no method of measurement reported by the 
authors related to the specificity of the IHC staining methods used. There are many instances of 
false positives related to immunostaining methods. Due to these concerns, the CDC working 
group determined the authors’ conclusions negated (CDC, 2012).  
Molecular mimicry. Most autoimmune diseases reportedly caused by the HPV vaccine 
are proposed to have occurred via molecular mimicry. Molecular mimicry is the theory that 
when viral human-like proteins and peptides in the form of antigens are introduced to the body, 
the immune system becomes confused between self and non-self. Because the invading antigen 
has similar proteins and peptides to those found in the body, the immune system initiates a 
continuous inflammatory response against the protein sequence naturally found in the body, 
causing an autoimmune disease (Holland et al., 2018). There are several instances where 
molecular mimicry is known to occur, albeit as a result of pathogenic infection, not vaccination. 
For example, when an individual is infected with group A streptococcus, the body forms an 
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immune response against it. However, a protein found in the group A streptococcus sequence 
mimics a protein found within the myocardium. This similarity causes the body to fight its own 
tissues, resulting in the autoimmune disease known as rheumatic fever, which can lead to 
rheumatic heart disease (CHOP, 2017).  
One study identified similar heptapeptide motifs between several human proteins and the 
HPV16 polyprotein found in the vaccine (Kanduc, 2009). However, the probability of these 
exact proteins occurring in the correct sequence is small. Even if this did occur, it is known that 
molecular mimicry alone is not sufficient to initiate an autoimmune response. Other factors such 
as pathogenic infection, tissue damage and chronic inflammation would be necessary as well. 
There was a study done on a vaccination for Lyme disease, which contains a very similar epitope 
to the human lymphocyte function-associated antigen 1 (LFA-1). Lyme disease itself is known to 
cause arthritis due to this similarity. However, there was no increased incidence of arthritis in 
those who received this vaccine (Vadalà, Poddighe, Laurino & Palmieri, 2017). Furthermore, 
natural infection with HPV does not cause autoimmune disease. The HPV virus, when caught 
naturally, replicates itself thousands of times creating a much stronger immune response than the 
vaccine, which does not replicate at all and consists of just one protein from nine strains of the 
virus (CHOP, 2017). This combined evidence indicates that autoimmune disease resulting from 
the HPV vaccine is highly unlikely, if not impossible. 
Conclusion 
History and evidence-based practice have proven vaccines to be efficacious, safe, and 
necessary. However, vaccine resistance has as long a history as vaccines themselves. The HPV 
vaccine is one of the more recent vaccines to fall under scrutiny. The relevance, efficacy and 
particularly, safety of the HPV vaccine are frequently disputed. There have been claims of 
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autoimmune disease onset, infertility and even death occurring after receiving the HPV vaccine. 
These claims have been largely refuted by multiple peer-reviewed, large-scale studies. However, 
despite the evidence, the use of the HPV vaccine is still questioned. According to the research, it 
is clear the efficacy of the HPV vaccine in reducing infection, cervical lesions and multiple types 
of cancer outweigh the risks, since such risks have yet to be proven. Implications for practice 
may include more thorough education on reasons for vaccine refusal for practitioners, so that 
patients are able to receive accurate information about the issues they perceive with vaccines. 
Nurses can support HPV vaccination by promoting patient and family health literacy on the risks 
associated with not receiving the vaccine, as well as the proven safety of the vaccine. It is 
important moving forward that doctors and nurses understand the reasons for HPV vaccine 
refusal, so they may be better prepared to combat them. This increased awareness and education 
may assist in increasing HPV vaccine compliance, thereby decreasing infection rates, cervical 
lesions, and the occurrence of cancer.  
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